Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKMH5L)

• Drug Name: 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one Drug Info
• Synonyms: 5-(4-Phenoxybutoxy)psoralen; 870653-45-5; UNII-A62C114Q0Q; CHEMBL444449; A62C114Q0Q; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-; 4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-(4-phenoxybutoxy)-; C21H18O5; 4-(4-Phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one; 7h-furo[3; 4-(4-phenoxybutoxy)-; 2-g][1]benzopyran-7-one; 5-(4-phenoxybutoxy) psoralen; GTPL2554; SCHEMBL2585454; CTK8F0318; DTXSID80461776; 5-(4-phenoxybutoxy)psoralen

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11302540
  CAS Number: CAS 870653-45-5
  TTD Drug ID: DMKMH5L

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated potassium channel Kv1.5 (KCNA5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[5]
BMS-919373	DMN28WK	Atrial fibrillation	BC81.3	Phase 2	[6]
IQB-9302	DMET0H4	Pain	MG30-MG3Z	Phase 1	[7]
XEN-D0103	DMR0U4V	Atrial fibrillation	BC81.3	Phase 1	[8]
BMS-394136	DMGDJQR	Arrhythmia	BC9Z	Phase 1	[9]
XEN-D0101	DMU0V45	Atrial fibrillation	BC81.3	Phase 1	[10]
T-226296	DMJ6P9U	Obesity	5B81	Preclinical	[5]
Zatebradine	DMNYKOT	Angina pectoris	BA40	Terminated	[11]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[12]
clofilium	DMQ37OP	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Calcium-activated potassium channel (KCN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[14]
Charybdotoxin	DMKN345	Scorpion envenoming syndrome	8D43	Approved	[15]
ICA-17043	DMRFY7I	Alzheimer disease	8A20	Phase 2	[16]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	DMQEJVU	Conjunctival fibrosis	9A61.3	Investigative	[2]
4-fluorophenyl-2,2-diphenylacetamide	DMI03KV	Discovery agent	N.A.	Investigative	[16]
N-methyl-2,2,2-triphenylacetamide	DMQGRMO	Discovery agent	N.A.	Investigative	[16]
TRIPHENYLMETHANAMINE	DM3CQIZ	Discovery agent	N.A.	Investigative	[16]
N,N-dimethyl-2,2,2-triphenylacetamide	DM9XZJN	Discovery agent	N.A.	Investigative	[16]
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide	DMFV76H	Discovery agent	N.A.	Investigative	[16]
2,2,2-tris-(3-fluorophenyl)-acetamide	DMJXAF7	Discovery agent	N.A.	Investigative	[16]

Drug(s) Targeting Voltage-gated potassium channel Kv1.3 (KCNA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Debio-0824	DMV401D	Psoriasis vulgaris	EA90	Phase 1b/2a	[17]
Dalazatide	DMJ1NG4	Inclusion body myositis	4A41.2	Phase 1b/2a	[18]
UK-78282	DMKBILF	Inflammation	1A00-CA43.1	Terminated	[19]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[12]
2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide	DM31E6J	Discovery agent	N.A.	Investigative	[20]
correolide	DMACH7K	Discovery agent	N.A.	Investigative	[21]
Correloid	DM5ISQK	Discovery agent	N.A.	Investigative	[22]
CP-339818	DMTJOWH	Discovery agent	N.A.	Investigative	[19]
5-(4-Phenylbutoxy)psoralen	DM3QFCV	Discovery agent	N.A.	Investigative	[23]
[1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine	DMH3BG5	Discovery agent	N.A.	Investigative	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel (KCN)	TTMNI76	NOUNIPROTAC	Inhibitor	[2]
Voltage-gated potassium channel Kv1.3 (KCNA3)	TTY3UE6	KCNA3_HUMAN	Inhibitor	[3]
Voltage-gated potassium channel Kv1.5 (KCNA5)	TTW0CMT	KCNA5_HUMAN	Inhibitor	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2554).
• [2] Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
• [3] Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70.
• [4] Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
• [5] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
• [7] Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
• [11] DOI: 10.1161/01.CIR.94.3.562
• [12] Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.
• [13] Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
• [14] Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
• [15] Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
• [16] Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
• [17] Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56.
• [20] Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4.
• [21] Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30.
• [22] Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51.
• [23] Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74.
• [24] Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83.